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Abstract 
This project to improve provider screening for breast cancer susceptibility (BRCA) gene 
mutations was implemented in a primary care clinic in Western Kansas.  The purpose of this 
quality improvement project is to determine if a BRCA gene mutation educational session, 
discussing Hereditary Breast and Ovarian Cancers (HBOC), screening guidelines and 
implications of screening, among primary care providers, will increase provider’s knowledge.  
Before and after the interventional BRCA educational session, the primary outcome, provider 
BRCA knowledge, was measured by use of a questionnaire titled “Questions for Survey for Birth 
Care Health Care Clinicians.” With the use of the McNemar Statistical test, paired data was 
analyzed, but there was no statistically significant change from pre-education questionnaire to 
post-education questionnaire.  A descriptive statistics table illustrates the impact on certain 
questions with the highest significance of 0.125.  This topic is highly impactful because breast 
cancer is the second deadliest cancer among women, and possessing a mutation on either the 
BRCA 1 or BRCA 2 genes significantly increases a woman’s risk for cancer in her lifetime.  
Regular, intermittent screening of women for HBOC syndrome risk, with an evidence-based tool 
at well-woman visits, should lead to earlier intervention for prevention and early detection of 
breast cancer and ovarian cancer in women at highest risk. 
 Keywords: BRCA screening, primary care, HBOC, barriers to screening, education for 
providers, strategies to improve provider compliance 
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Improved BRCA Screening Among Women in Primary Care Following Provider Education 
 BRCA (BReast CAncer) genes, BRCA 1 and BRCA 2, work as tumor suppressors, which 
function by controlling the assembly of macromolecular structures that monitor segregation and 
duplication of chromosomes throughout the cell cycle (Venkitaraman, 2014).  When these genes 
have a mutation, they are more susceptible to human malignancies, particularly breast and 
ovarian tumors (Venkitaraman, 2014).  In the last 15 years, the rapid discovery of cancer-related 
genes has driven the field of hereditary risk assessment forward.  As a result of this as well as 
media portrayal, more patients are learning about BRCA genetic testing and the vital role it has 
in prevention and diagnosis.  Often, primary care providers’ knowledge is incomplete when 
examining genetic testing views and targeted cancer screening (Hamilton, Abdiwahab, Edwards, 
Fang, Jdayani & Breslau, 2017). 
Background and Significance 
 The Department of Health and Human Services (HHS), Healthy People 2020 has 
identified cancer care as one of the health concerns in the next 10 years to improve upon in 
America.  More specifically, two objectives identified include reducing the death rate of female 
breast cancer and increasing the number of patients who were counseled about cancer screening 
consistent with current guidelines (DHHS, 2016).  If this initiative is successful, a large portion 
of the United States population will be affected by improving prevention, detection, diagnosis 
and outcomes.   
Currently, among women in the general population, 12% will be diagnosed with breast 
cancer and 1.3% will be diagnosed with ovarian cancer during her lifetime (National Cancer 
Institute, 2015).  Contrariwise, 55-65% of women who possess a BRCA 1 and 45% of women 
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who possess a BRCA 2 mutation will be diagnosed with breast cancer in her lifetime.  Ovarian 
cancer is most frequent among BRCA 1 mutation carriers with a lifetime risk of 39% and 11-
17% risk for BRCA 2 mutation carriers (National Cancer Institute, 2015).  According to an 
article published in the Pruthi, Gostout & Lindor (2010), “In the United States in 2009 alone, 
there were approximately 192,370 new cases of breast cancer and 21,550 new cases of ovarian 
cancer.  That same year, 40,170 people died from breast cancer and ovarian cancer deaths were 
estimated at 14,600.”  It is important to reiterate that although few breast cancers are attributable 
to inheritance of a mutation on the BRCA genes, the risk associated with a confirmed mutation is 
as high as 85% and can make a profound impact on the life of the patient with the mutation 
(Lipsky et al., 2009). 
Economic Impact 
 Death rates are notable when addressing female cancers, but economically, it is important 
to consider the economic impact when female patients are diagnosed with cancer.  In an article 
published by the American Journal of Preventive Medicine, it was determined that between 1970 
and 2008, there were 225,866 deaths associated with breast cancer, which could account for 
approximately 7.98 million years of potential life lost (YPLL) (Ekwueme et al., 2014).  This 
same article utilized Joinpoint regression modeling to determine that in 2008 due to the YPLL, 
the estimated productivity loss was $5.49 billion and approximately $1.10 million in individual 
lifetime lost earnings from breast cancer specifically (Ekwueme et al., 2014).   
 The United States Preventive Services Task Force (USPSTF) (2015) issued 
recommendations for BRCA screening in the primary care setting.  These recommendations 
outline that for any woman with a family history associated with an increased risk of mutations 
in the BRCA1 or BRCA2 gene, it is recommended with moderate certainty that the advantage of 
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screening, testing and subsequent early intervention is appropriate.  This screening should begin 
once women have reached 18 years of age, the age of consent, and primary care clinicians should 
be regularly discussing changes in family history with these patients (USPSTF, 2015).   
Local Issue 
 Screening, by definition and for the purpose of this paper, is the evaluation of a patient’s 
family history with the utilization of a tool to determine if she is at an increased risk of breast or 
ovarian cancer due to a deleterious mutation on the BRCA gene that predisposes women to 
HBOC cancers.  For those providers who do not encounter this population of patients on a daily 
basis, and do not routinely utilize screening guidelines in conjunction with a screening tool, the 
guidelines may be difficult to interpret.  This difficulty of interpretation could be a reason that 
very few primary care practitioners are evaluating patients for these deleterious mutations 
(Bellcross, Kolor, Goddard, Coates, Reyes & Khoury, 2011). 
 Specifically, rural communities such as Dodge City likely face barriers to receiving 
preventive care, specifically, monitoring for breast cancer, which decreases their chances of early 
detection (Lipsky et al., 2009).  If providers further understand the implications of BRCA 
screening in the primary care setting, improvements in the identification of HBOC syndrome in 
patients is attainable (Nair et. al, 2015). 
Diversity Considerations 
 BRCA mutations can occur among any person with family history of deleterious 
mutations to this gene; however, there have been certain cultures among whom are considered to 
be at higher risk, including the Ashkenazi Jewish population (Ferla et al., 2007).  The 
Washington State Nurses Association reports that barriers exist among rural practitioners, which 
prevent adequate healthcare administration (Lipsky et al., 2009).  These barriers include: 
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negative patient attitude about mammography, lack of understanding regarding reimbursement 
for testing, lack of health insurance, lack of accessible imaging sites, physical disabilities, 
communication barriers and cultural norms and attitudes about disease processes (Lipsky et al., 
2009).  Furthermore, the population of rural communities is usually poorer, older and 
considerably less well educated compared to patients in urban communities (Lipsky et al., 2009). 
 The educational program was implemented at a family practice clinic in western Kansas.  
Of note, the city of project implementation has a 57.5% Hispanic population so cultural 
considerations were made (United States Census Bureau, 2016).  The student investigator does 
not speak Spanish fluently, but the manager of the practice asserts that there is always someone 
available on staff to provide translation services to patients during the family history data 
collection, if necessary.  According to Ramirez et al. (2013), breast cancer deaths rank higher in 
Latina women compared to Caucasian women, most likely because it is diagnosed and treated 
later when the cancer is more advanced and treatment is much more complex.  Unfortunately, 
cultural barriers among Latina women have often been ignored because language barriers and 
social norms exist among this population, including respect, family-centeredness, dignity and a 
high value of being a dedicated wives and mothers, which make receiving timely treatment more 
difficult. 
Another barrier to preventative care is that 21% of the population does not have health 
insurance in Dodge City, KS (United States Census Bureau, 2016).  Because of this, uninsured 
patients may not seek counseling or follow-up visits as warranted (Sussner, Jandorf, Thompson 
& Valdimarsdottir, 2012).  Another barrier among this population of patients is that 14.8% of 
patients are living in poverty (United States Census Bureau, 2016).  If providers utilize a 
screening tool, such as the Ontario Family Health Assessment Tool (OFHAT) (see Appendix A) 
PROJECT PROPOSAL PAPER 
 
7 
to assess a family history that may be associated with an increased risk of a mutation on the 
BRCA gene, the guidelines outline that that patient should then be referred to a genetic counselor 
(USPSTF, 2015), which would be an additional cost to the patient.  This may be a barrier to the 
referral process if the patient cannot afford to see a genetic counselor. 
Rural practitioners often face barriers to providing adequate preventative health care and 
although Dodge City has access to BRCA testing kits through Myriad Genetics, and diagnostic 
imaging, mammography, ultrasonography, and MRI, there is no access to a genetic counselor in 
town.  Because of this, patients would be referred to a genetic counselor in a larger urban area.   
Problem & Purpose 
Problem Statement & Purpose Statement 
 Despite increasing knowledge and evidence regarding the use of genetic testing to assess 
a woman’s predisposition to breast, ovarian, tubal and peritoneal cancers, significant barriers 
remain in appropriately screening women for their risk for having a BRCA gene mutation 
(Lipsky et al., 2009).  Encouragingly, providers can take certain measures to ensure they are 
providing appropriate care to their patients, including: learning about the community, setting 
goals among staff and creating incentives for positive change in behavior (Lipsky et al., 2009).  
The purpose of this BRCA screening project was to determine if the BRCA screening 
educational session regarding hereditary breast and ovarian cancers, among primary care 
providers, will increase providers’ knowledge related to BRCA risk screening. 
Intended Improvement 
 The United States Preventive Services Task Force has provided guidelines for screening 
patients at added risk for breast, ovarian, tubal and peritoneal cancers (USPSTF, 2015).  
Bellcross et al. (2011) conducted a study among United States primary care providers, which 
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reported that out of 1,500 physician respondents in a primary care setting, 25% of providers 
reported having ordered at least one BRCA test within the last year.  Excluding pediatricians 
from the results did improve these percentages to 93% aware of BRCA and 30% testing ordered 
(Bellcross et al., 2011).  This further supports the hypothesis that although providers may read 
the new guidelines, most will not utilize the new guidelines if they are not comfortable with them 
(Bellcross et al., 2011). 
 In a recent study conducted regarding provider BRCA knowledge, Cohn (2014) reports 
that, generally speaking, primary care providers recognize their knowledge deficits regarding 
genetics testing and express an aspiration for further education.  As such, health care providers in 
the primary care setting, especially those in rural communities, should be educated about the 
usefulness of family history screening and if positive response, a more in-depth screening with a 
tool (such as the OFHAT) would be warranted.  Providers should also understand the utility of 
the results of the tool as well as the effect it can have on the future care for a woman with a 
deleterious mutation on BRCA genes.  The focus of this project was primarily increasing 
provider knowledge regarding HBOC syndrome, BRCA screening and how to utilize the 
guidelines.  A secondary purpose, which was not measured during this project, would be the 
consequences of providers understanding screening recommendations which would improve the 
number of patients who are being appropriately screened with a BRCA screening tool. 
Facilitators and Barriers 
 For the implementation of this project, there were facilitators and barriers alike.  The 
family practice clinic in western Kansas, the location of project implementation, is a 
facilitator.  Each provider with whom the student investigator works is a facilitator, and currently 
at this practice, there are 5 providers.  The Advanced Practice Registered Nurse with whom the 
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student investigator worked is most notably a facilitator at this practice location because she 
worked closely with the student investigator to ensure that the project was implemented 
seamlessly.   
One barrier that the student investigator faced was the inability of one provider to attend 
and listen to the educational opportunity regarding screening for BRCA mutations in the primary 
care setting.  Certainly, agreeing to such an educational class not only takes time out of 
providers’ days, but it also encourages them to practice differently, than perhaps the ways in 
which they are accustomed.  Another barrier that exists is that of the language barrier. If the 
providers do not speak Spanish fluently, they will need to utilize a translator in order to ensure a 
thorough family history is obtained.  Finally, there is not access to a genetic counselor to whom 
patients can be referred in the city of project implementation.  Instead, they must first be seen by 
their practitioner and then referred to a genetic counselor in are larger town, which is a barrier. 
 If this project is found to make a significant difference in provider knowledge regarding 
BRCA gene mutation risk, it could be the impetus that such an educational class could be made 
available to other primary care offices across the country in order to provide the necessary 
educational information to providers.  Factors that may inhibit sustainability of this intervention 
after the project are barriers previously discussed, as well as an inability of providers to dedicate 
time to the cause, unwillingness of providers to change their practice techniques, and lastly, if 
they see patients who are unaware of their family history.  If a patient is unaware of her family 
history, use of the OFHAT screening tool or any other screening tool would not be useful in this 
patient. 
Review of Evidence 
Primary PICOT 
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Among providers who perform annual well-women exams, does an educational program 
about hereditary breast and ovarian cancer (HBOC) syndrome and the importance of screening 
for high-risk BRCA patients, compared to usual care, increase provider knowledge? 
Search Strategies 
 An extensive literature review was conducted using Cumulative Index to Nursing and 
Health Literature (CINAHL), PubMed, Medline databases and the use of Google Scholar search 
engine in preparation for the synthesis of evidence.  Study designs that were utilized included 
seven cohort and observational studies (Level III evidence), seven guidelines, six non-
randomized control trials (Level II evidence), three observational studies (Level IV evidence), 
two randomized control trials (Level I evidence) and one meta-analysis study (Level I evidence) 
(Appendix B).  Key search words included: BRCA, screening, primary care setting, barriers to 
screening, randomized control trials and provider knowledge and HBOC Syndrome.  Inclusion 
criteria included screening in the primary care setting, provider knowledge, risk assessment tools 
and original research data.  Exclusion criteria included ethical considerations for genetic testing, 
and literature not in English.  The guidelines utilized for this paper were provided by the United 
States Preventive Services Task Force (2013), The National Cancer Institute (2015) and the 
Centers for Disease Control and Prevention (2015). 
Evidence 
Screening Recommendation 
 In 2013 the United States Preventive Services Task Force (USPSTF) published 
guidelines on the annual routine screening of adult patients who present to primary care clinics 
with a family history of cancers of breast, ovaries, fallopian tubes or peritoneum.  Women with 
this family history should be screened with an approved screening tool (such as the OFHAT) to 
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identify a family history, which may be associated with a mutation on the BRCA1 or BRCA2 
genes.  The guideline further explains that should a patient positively screen with one of the 
approved tools, she should be referred for genetic counseling, and possible subsequent genetic 
testing (USPSTF, 2013).   
 It should be delineated that for those patients who do not have a direct family history of 
any of the aforementioned cancers, it is not recommended to screen these women with one of the 
approved screening tools outlined in the USPSTF guidelines; however, for women who have a 
family history associated with BRCA mutations, the USPSTF maintains with moderate certainty 
that the net advantage for genetic testing, and potentially, early intervention is considerable 
(USPSTF, 2013).   
 The National Cancer Institute (NCI) also approves of these guidelines (National Cancer 
Institute, 2011). According to an article published by the NCI, BRCA1 and BRCA2 gene 
mutations are moderately rare in the general population.  Given this information, genetic testing 
for patients without cancer should be performed only if family history suggests a possible 
presence of a deleterious mutation (National Cancer Institute, 2011).  The NCI also purports that 
screening tools, such as BRCA screening tools, are useful in identifying family history factors, 
which may indicate an increased likelihood of a BRCA mutation.  These factors include: breast 
cancer diagnosed before age fifty, both breast and ovarian cancers in either the same woman or 
same family, cancer in both breasts in the same woman, multiple breast cancers, cases of male 
breast cancer, two or more primary types of BRCA1 or BRCA2-related cancers in a single 
family member, and Ashkenazi Jewish ethnicity (National Cancer Institute, 2011).   
 The NCI does not recommend genetic testing for a BRCA mutation without first 
discussing the testing with a genetic counselor (NCI, 2011).  This is in alignment with the 
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USPSTF guidelines, in that, if a patient is positively screened in the primary care setting, she 
should be referred to genetic counseling prior to any genetic testing (USPSTF, 2013). 
Rationale for Screening 
 Kolor (2014) notes that while most cancers that occur in women are not hereditary, some 
certainly are.  In fact, for those women who have a BRCA gene mutation, the lifetime risk of 
developing ovarian and breast cancers are greatly increased, specifically in the absence of 
intervention.  In an effort to depict the importance of screening, a woman’s risk of breast cancer 
increases from 45% to 65% by the age of 70 if there is a mutation on the BRCA gene (USPSTF, 
2015).   The USPSTF (2015) also determines that the overall benefit of testing for BRCA 
mutations is moderate, while the harms of detections are small.   
 In order to further provide rationale for screening with a screening tool, the National 
Cancer Institute (2011) notes that if a person screens positively with an approved family HBOC 
history screening tool (such as the OFHAT) for a BRCA genetic mutation, then undergoes 
genetic counseling and subsequent BRCA testing and is found to be positive, she now has the 
opportunity to utilize increased diagnostic imaging studies in order to diagnose a cancer in earlier 
stages, rather than late stages.  Furthermore, if a patient is positive for a genetic mutation on the 
BRCA gene, she can then share this information with her family members who may be able to 
take advantage of increased monitoring and testing as well (NCI, 2011). 
 Lipsky et al. (2009) describes that breast cancer is the most common cancer in women, 
and in the United States a breast cancer is diagnosed every 3 minutes in women.  Perhaps even 
more sobering, is that every 13 minutes, a woman dies from breast cancer.  The student 
investigator outlines that a fundamental component to caring for patients is identifying those 
patients who are at increased risk of developing a cancer (Lipsky et al., 2009).  Knowledge of an 
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individual’s gene mutation status allows patients to utilize proactive medical management, which 
may include enhanced imaging, medical interventions or even prophylactic surgery (Cohn, 
2014).  One important piece to demarcate is that a genetic mutation cannot predict with certainty 
that a person will definitely develop cancer in the future.  Instead, the mutation predisposes 
patients to BRCA-associated cancers, but knowledge of this may allow for prevention measures, 
which can improve patient outcomes (Loescher et al., 2009). 
 It could be argued by providers that they do not possess the time in a visit to utilize a 
screening tool with each woman with a family history of breast, ovarian, tubal or peritoneal 
cancers.  Family history-screening questionnaires, such as the OFHAT tool have been 
underutilized for years, but according to a study published by Armel et al., (2011) in the Journal 
of Genetic Counselors, these family history-screening questionnaires are desirable to patients and 
may provide a more efficient means of counseling, by reducing the time spent by the provider.  If 
these family history-screening questionnaires could be utilized more effectively in the primary 
care clinic, and providers understood the implications and utility of these tools, perhaps more 
providers would utilize these tools to aid in a smoother and prompter visit. 
Provider Education 
 A randomized control trial by Rubinstein et al. (2011) determined that family history is 
an established risk factor for breast cancer and ovarian cancer, but unfortunately, proper family 
health history is rarely obtained in practice and because of this, patients are not being routinely 
screened appropriately.  McCarthy et al. (2013) performed a population-based study to determine 
whether or not provider recommendations played a vital role in subsequent BRCA testing.  The 
study concluded that in fact, physician recommendations are a vital determinant in the use of 
genetic testing.  Sadly, among high-risk women, failure to receive BRCA screening or a 
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recommendation for testing from their provider resulted in relatively late stage at diagnosis 
(McCarthy et al., 2013).   
 In a randomized control trial by Cox et al. (2012), of the providers who recommended 
any cancer screening and testing to their patients, it was for the following reasons: to guide 
future detection management (75%-80%), the patient met practice guidelines (82%-86%), to 
guide prophylactic management decisions (76%-80%), and because their patients requested the 
test (79%-81%).  Although it is apparent that patient request certainly guides provider decisions, 
patient requests of testing is only valuable if the patient is aware of what the BRCA gene test is.  
In many populations, patients are completely unaware that he or she may be at an increased risk 
of cancer.  In fact, Lipsky et al. (2009) explains that residents of rural areas face many barriers to 
obtaining cancer screening and this can be related to negative patient attitudes, cultural attitudes 
about disease processes, lack of health insurance, lack of understanding of insurance, lack of 
monetary means, and communication barriers, which is why the family screening tool is vital.  
 Bellcross et al. (2011) performed a study to determine the level of awareness and 
utilization of BRCA testing among United States primary care providers.  This study did 
conclude that although utilization of BRCA testing has risen, many providers do not recognize 
that family history patterns dictate BRCA screening per the USPSTF guidelines.  If providers are 
not identifying these high-risk individuals, a disservice is being done to the patient.  Pruthi, 
Gostout & Lindor (2010) describe that obtaining a basic but comprehensive family history along 
with an evaluation of patient’s risk factors are vital steps to assessing the risk of breast and 
ovarian cancer. 
Theory 
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 The theory for this project is the Ace Star Model of Knowledge Transformation 
(Appendix C).  In order for this project to be successful, an organizational change will need to 
occur among the practice and the providers.  With the use of the Ace Star Model, five major 
stages of knowledge transformation will be delineated, which will aid in the successful transition 
to increased screening for potential BRCA mutation carriers, which will improve patient 
outcomes (Stevens, 2012).  The five major stages include discovery, which is the knowledge 
generating stage.  The student investigator has conducted a thorough review of literature to 
collect more knowledge about the topic.  The second stage is evidence, which incorporates the 
knowledge into a meaningful statement.  The student investigator created a problem statement to 
identify the current problem as well as the purpose statement to identify the need in the clinic.  
The third stage includes translation to guidelines, which has occurred by translating the evidence 
and guidelines into a solution to the problem.  The fourth stage involves integration into practice, 
which will occur in the upcoming months as this project is implemented into practice.  The final 
stage is that of outcome evaluation, which will occur at the end of the educational session with 
the providers and following statistical analysis (Stevens, 2012).  
Methods 
IRB Approval, Ethical Issues, Funding 
 Primary IRB approval was received from University of Missouri Kansas City (UMKC) 
Institutional Review Board (IRB) since the project site does not maintain their own IRB.  The 
project was approved as non-human subjects quality improvement project.  There are no known 
risks to the participants; the providers in this population will undergo no harm during this project 
and are free to withdraw from the project at any time with no repercussions.  A flowchart 
depicting the project implementation is outlined in Appendix D.  The total estimated cost of this 
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project is $1,800 (Appendix E).  The largest amount of funding will be used for development of 
the provider education program.  The student investigator will prepare the educational 
program.  The provider-training luncheon will amount to about $200 and the handouts for 
providers are estimated to cost about $200.  No applications were submitted for scholarship or 
grants for project funds, though a $500 scholarship was awarded to the student investigator to aid 
in the cost of dissemination. 
Setting and Participants 
 The setting of this project has taken place at a family practice clinic in western Kansas.  
This project involved an initial educational session with the providers individually to discuss 
HBOC Syndrome and the important role that screening women can play in clinical practice.  
Current guidelines set forth by the United States Preventive Services Task Force (USPSTF) (see 
Appendix F) was discussed regarding BRCA screening with the OFHAT tool, of any adult 
woman with a family history of breast, ovarian, tubal or peritoneal cancer for BRCA mutations 
(USPSTF, 2015).  Inclusion criteria for this project included all providers within the participating 
clinic who perform wellness exams on adult women.  Exclusion criteria included those providers 
who do not care for adult women patients, those providers who do not speak English, and those 
who do not wish to participate in the project or have not given consent to participate.  
Evidence Based Practice Intervention 
 The evidence based intervention for this project is provider education in order to promote 
knowledge about screening guidelines for patients who are at increased risk for BRCA mutations 
as well as the importance of collection of current family history data.  Cohn et al. (2014) explains 
that few providers recognize the National Comprehensive Cancer Network’s risk assessment 
guidelines for identifying BRCA mutation and thus, are unfamiliar with subsequent 
PROJECT PROPOSAL PAPER 
 
17 
management.  Detailed family history is vital at routine medical visits in a primary care setting 
and if this occurs, more patients would be appropriately screened with a screening tool for 
deleterious mutations on the BRCA genes (Rubenstein et al., 2011).  Specifically, when a patient 
presents for a routine wellness exam, the provider should be inquiring about recent changes in 
family history of cancer.  If the patient has any family history of breast, ovarian, tubal or 
peritoneal cancer, she should then be further screened by the provider with one of many 
approved screening tools, such as the OFHAT tool, as outlined in the recommendation statement 
from the USPSTF.  This project aims to educate providers about the importance of thorough 
family history data collection and screening for potential BRCA gene mutations while utilizing a 
screening tool, based on that family history data.  Provider knowledge was measured by a pre-
test before the educational intervention and a post-test directly after the educational session. The 
test that was utilized is titled the “Questions for Survey for Birth Health Care Clinicians” 
(QFSFBHCC) (Ledingham, 2014) (see Appendix G) 
 All providers at Medical Practice Associates of Western Kansas who see adult female 
patients for well woman exams were recruited to participate in this educational experience, 
though 5 participated.  Initially, providers completed the QFSFBHCC pre-test regarding BRCA 
screening knowledge.  Informed consent was implied when providers participated in the 
completion of the questionnaire.  The student investigator then conducted the 20-minute BRCA 
Screening Educational Session with the recruited providers individually.  Handouts provided by 
the American Cancer Society (see Appendix H) and the guidelines provided by the USPSTF (see 
Appendix F) were utilized to ensure retention of subject matter.  Following the educational 
session, the providers were asked to fill out the QFSFBHCC post-education assessment in order 
to determine whether their understanding of BRCA screening changed.  If the goal is met, 
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following the educational session, the providers should have a better understanding of which 
patients should be additionally screened with the OFHAT tool as well as what to do with the data 
once it is collected.  Specifically, the OFHAT tool outlines that if a patient scores a value of 10 
or greater, she should be referred for genetic counseling; this is considered a positive screen and 
is considered to be high-risk for potentially possessing a mutation on one of the BRCA genes. 
 The student investigator conducted recruitment for providers in this practice who care for 
this population of patients, so it could be replicated in any family practice or internal medicine 
clinic.  The project implementation took about two months to complete and an addition 3 months 
for data analysis.  Five providers participated in the project pretest, intervention, and posttest. 
Change Process, EBP Model 
 Along with utilizing the ACE Star Model of Knowledge Transformation to help guide 
this project, the student investigator will also utilize the Promoting Action on Research 
Implementation in Health Services (PARiHS) Method.  This framework helped to guide the 
implementation of research into practice by the use of three key elements; evidence, context and 
facilitation (National Collaborating Centre for Methods and Tools, 2011).  This model supports 
the intervention because it helps to describe how to properly and successfully implement 
research into practice by means of an organizational issue as opposed to and individual issues 
(National Collaborating Centre for Methods and Tools, 2011). 
 This PARiHS model also works well with this topic and project focus because it allows 
for reproducibility of the project in other clinics.  Due to the low cost, reproducibility and the 
ease of use of this method, sustainability of this project is quite likely. 
Study Design 
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 This project is a quality improvement project in order to improve provider knowledge.  A 
single group pretest and posttest design on a convenience sample was utilized.  Providers in the 
primary care practice were educated about the current guidelines regarding screening with the 
OFHAT tool for BRCA mutations in adult women.  The student investigator compared the data 
from the QFSFBHCC pre-test and the QFSFBHCC post-test by use of the McNemar test to 
determine whether or not providers gained knowledge with the BRCA Screening Educational 
Session. 
Validity 
 The student investigator established internal validity by investigating the providers’ 
understanding and knowledge of BRCA screening.  Factors that may influence the internal 
validity of this project include providers’ previous knowledge of BRCA screening, experience 
with BRCA screening in the past, and providers’ personal experiences and attitudes toward the 
topic.  Maturation is described in research as the changes in the dependent variable due to normal 
developmental processes.  This likely would not cause a threat to internal validity due to the 
short project timeline.  External validity can be achieved because of the reproducibility of this 
topic.  Any clinic with providers willing to attend an educational session and those clinics with a 
patient population of adult, female women would be able to reproduce this project. 
Outcomes to be Measured 
The primary outcome to be measured for this project is provider knowledge related to 
HBOC Syndrome and BRCA screening.  Provider knowledge related to current guidelines will 
also be assessed with the pre and posttest provided to practitioners.  An associated outcome that 
will not be measured for this project is education for providers regarding what to do with the 
information gained from utilizing a screening tool (see Appendix J). 
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Measurement Instruments 
 The measurement instrument that will be used to assess provider knowledge regarding 
BRCA screening is the “Questions for Survey for Birth Care Health Care Clinicians” 
(Ledingham, 2014).  Permission was received from the author for use of this tool for 
implementation of this project (Appendix K).  This tool has been used before in similar research, 
but validity and reliability have not been determined at this time. 
 The BRCA risk assessment tool that will be discussed with providers during the 
education is the Ontario Family History Assessment Tool (OFHAT).  This tool was developed 
for use by providers to determine those patients who should be referred for genetic counseling.  
The tool was indicated in the literature to be effective in identifying those patients who are later 
found to be mutation-positive (Gilpin, Carson & Hunter, 2000).  The tool is identified in the 
USPSTF recommendation statement as an approved screening tool for use with women with an 
increased risk of BRCA gene mutation.  Both validity and reliability have been established. 
Quality of Data & Analysis Plan 
 Following the recruitment period, quality of data was determined.  Five total providers 
participated in this quality improvement project.  Following data collection, SPSS was utilized to 
run McNemar’s test was utilized to analyze the participant’s responses pre and post intervention.  
Data was not statistically significant in this project.  Future work should include further 
education with providers and interprofessional staff to ensure proper screening occurs according 
to guidelines. 
Results 
Setting & Participants 
 This quality improvement project was implemented at a family practice clinic in western 
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Kansas.  The implementation was projected to span over one month’s time, but the providers 
preferred that the student investigator discuss the topic with each provider individually instead of 
during one session.  As such, the project timeline was expanded and lasted 4 months to obtain all 
data from each participant.  The participants included 5 providers within the family practice 
clinic.  There was one nurse practitioner and 4 physicians among the participants. 
Intervention Course, Actual 
 A major component of the intervention includes the educational session with each 
individual provider.  Although the pre-educational questionnaire and post-educational 
questionnaire provide important information, given the fact that this project is a quality 
improvement effort, the education for providers is a vital component.  This component occurred 
following the completion of the pre-educational session questionnaire by each provider.  During 
educational sessions, information was provided to clinicians from the USPSTF, and the 
American Cancer Society to outline guidelines for screening for those patients who are at an 
increased risk of a deleterious mutation to the BRCA genes.  The clinic where this project was 
implemented was quite busy, so the student investigator had to accommodate to each provider’s 
schedule in order to obtain the data.  There are six total providers in clinic, but one provider in 
the clinic was unable to take part, which left the final participant group at five providers. 
Outcome Data  
 The primary outcome that was measured in this quality improvement project was 
provider knowledge.  Provider knowledge was initially assessed by use of the QFSFBHCC tool 
in order to gain an understanding of provider’s knowledge of HBOC syndrome and better 
understand their practice preferences for BRCA screening and testing.  Then, directly following 
the educational session with providers, they were asked to complete the QFSFBHCC 
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questionnaire again.  Pre and post-test data was compared utilizing SPSS and the McNemar Test 
with binomial distribution.  SPSS did not run data on those questions that showed no change 
between the pre and post-test, therefore, missing data was excluded from the data table (see 
Appendix L).  The results of this quality improvement project are best displayed with use of 
descriptive statistics (see Appendix M).  The table represents an abbreviation of the questions 
that are on the questionnaire to better understand the pre and post-test answers.  Though the 
project did not yield statistically significant data, the providers in the clinic state that they are 
more aware of BRCA screening and testing guidelines and are more likely to utilize a genetic 
counselor prior to testing as recommended by the USPSTF. 
Discussion 
Successes 
 For this quality improvement project, the data retrieved was not statistically significant, 
however one vital success that was recognized following this project was an increase in 
provider’s awareness regarding the importance of screening patients with an increased risk of 
possessing mutations on the BRCA genes.  Prior to the educational sessions, through casual 
conversation with the student investigator, the providers had limited knowledge of the guidelines 
and were unaware of the importance of utilizing a genetic counselor.  Although the data does not 
reflect significant knowledge increase, the providers have verbally expressed to the student 
investigator that they feel more comfortable using screening tools for this population of patients 
and are more likely to utilize the current guidelines from the USPSTF. 
Study Strengths 
 This study possessed elements that provided support for the proposed intervention.  The 
first, and most important element was the provider and staff at the clinic with whom the student 
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investigator worked.  All staff, whether involved in the project or not, were willing to assist in 
any way to make implementation of this project easier.  The nurse practitioner in this practice 
was beyond helpful and assisted the student investigator in arranging meeting times with all 
providers who participated in the project.  Another important element was the willingness of the 
participants to take time from their busy clinic day to discuss a quality improvement project with 
the student investigator.  Finally, though the setting was in a rural area, which made 
implementation from a geographic perspective difficult, it was a helpful element for project 
implementation that the clinic was small and there were not large numbers of providers with 
whom to work. 
Results Compared to Literature 
 Results from this quality improvement project were similar to those found in the 
literature.  According to Hamilton et al. (2016), there is a need to move beyond descriptive-type 
research questions regarding primary care provider’s knowledge of genetic testing and instead, 
focus on the gaps related to the implementation of advanced interventions and educational 
platforms that would increase providers’ knowledge regarding BRCA testing as well as promote 
effective, open communication between providers and patients.  The data from this project was 
not statistically significant and the most important data was gained following the use of 
descriptive statistics to measure pre and post data following a questionnaire.  
 Genetic mutation screening tools were created to identify an increased risk of possessing 
a harmful mutation.  According to Walker et al. (2015), risk assessment tools may increase 
patient intention to monitor for cancer, but additional interventions by the provider are necessary 
to increase appropriate screening behavior.  This represents the importance of educating 
providers who care for adult women, as they need to understand the importance of utilizing 
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screening tools as well as discuss screening with the patient as well as the importance of risk-
reduction strategies, if necessary. 
Limitations 
Internal and External Validity Effects 
 Due to the descriptive nature of this project, the student investigator was not trying to 
identify a causal relationship between two variables and as such, the internal validity is not as 
relevant as in other types of studies.  However, the student investigator was able to establish 
internal validity by only studying one variable, provider knowledge, which decreased the risk of 
confounding, thus promoting internal validity.  Maturation was also avoided in this study due to 
the short project timeline.  External validity can be gained because of the reproducibility of this 
topic.  Any clinic could implement this project if the providers are willing to attend an 
educational session as well understand the importance of potentially augmenting their practice 
related to BRCA gene mutation screening and testing. 
Sustainability of Effects and Plans to Maintain Effects 
 Sustainability of this project should be relatively easy to maintain as long as providers 
continue to stay current with guidelines for screening for this population of patients.  Any new 
providers in the clinic should be educated about current practices for screening.  Gains that were 
made should not weaken over time as long as providers are staying up-to-date on guideline 
recommendations. 
Efforts to Minimize Study Limitations 
 Many efforts were taken for this quality improvement project in order to minimize study 
limitations, but unfortunately limitations did still occur.  One impactful limitation was the small 
population size of only five providers.  Due to the size of the clinic and the relatively rural area 
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of practice, the population size could only have been expanded if the student investigator 
included other internal medicine or family practice clinics, but given the short period of time to 
implement the project, this was not feasible.  Another limitation of this study was the 
incremental findings following statistical data analysis.  Some data was excluded from the final 
analysis because there was no change from the pretest to the posttest and the data that was 
analyzed did not represent significant increase in provider knowledge.  Based on this 
information, follow-up research should focus on utilizing a less descriptive tool to measure pre 
and post knowledge, and perhaps an educational tool could be created to ensure all providers are 
being educated in exactly the same fashion with identical information presented.  Data 
limitations existed in this project because the data that was collected was not as helpful as it 
could have been to best measure the provider’s knowledge; however, the information is still 
helpful because it is widely-applicable for this population of patients in all parts of the world. 
Interpretation 
Expected & Actual Outcomes 
 The student investigator expected to increase provider knowledge regarding screening 
adult women in the primary care setting for an increased risk of BRCA gene mutations, and 
while the reported data was not statistically significant, this outcome was met.  Following the 
implementation, the student investigator discussed with the owner of the practice the possibility 
of building a screening tool into the electronic health record and the owner was receptive about 
this potential addition.  One unexpected result from this project was the providers’ interest in 
addressing gaps in their education regarding BRCA screening.  Among all of the providers in the 
clinic, each person expressed to the student investigator that he or she should more closely 
follow the guidelines and was going to start utilizing genetic counseling as the guidelines 
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recommend.  Initially, the student investigator planned to work with nurses as well as providers 
to increase compliance of screening, but due to a large Hispanic population of patients in this 
area, the translators who work with the nursing staff would also need to undergo Collaborative 
Institutional Training Initiative (CITI) education and there was little to no incentive for the 
translators to make this effort.  As a result, the providers were the only staff members who 
received the educational intervention. 
Intervention Effectiveness 
 The project data did not yield statistically significant results, though the providers in the 
clinic did discuss with the student investigator that they have a better understanding of the 
guidelines for screening as well as those patients who should be referred for genetic counseling.  
Because of this, the student investigator infers that the intervention was effective in this type of 
setting.  The setting in which this educational intervention would be most effective is any 
primary care setting in which providers care for adult women. 
Intervention Revision 
 One intervention modification that may have increased statistical improvement in the 
data would be to utilize a tool that was not descriptive, but instead had a right and wrong answer 
for each question that left no room for interpretation.  Then, if the educational session was 
focused around each of these questions to ensure each question was addressed, perhaps pre and 
post data would have been more revealing. 
Expected and Actual Impact to Health System, Costs and Policy 
 The cost of project implementation in this clinic was higher for the student investigator 
because the clinic was a 5-hour drive from the city of residence for the student.  Due to this, 
there was cost associated with travel including gas, wear on care and oil.  Furthermore, lodging 
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and food while in Dodge City, KS was also a cause for increase in price.  If staff of the clinic 
implemented this educational intervention in the future, these travel costs would be irrelevant.  
Economic sustainability for the intervention would be very likely due to the impact BRCA 
testing has on the economy.  According to D’Andrea et al. (2016), family-history based 
screening is possibly highly cost-effective, though further studies identifying high-risk women 
need to be done.  Moreover, Li et al. (2017) reports that testing breast cancer-associated genes 
could cost-effectively increase life expectancy for women at high risk for hereditary breast 
cancer.  
Conclusion 
Practical Usefulness of Intervention 
 This intervention improved provider knowledge and awareness about BRCA mutation 
screening in the primary care setting in western Kansas.  If this project is successful in other 
clinics, providers would feel more aware and confident about BRCA screening techniques and 
incorporating BRCA screening in practice.  Furthermore, if providers are educated appropriately 
regarding HBOC screening guidelines, this could lead to a decrease in the progression to 
advanced stage breast cancer, which leads to decreased health care costs (Birtwistle, 2014). 
Further Study or Implementation of Intervention 
 The provider educational session could be implemented in urban areas in primarily 
private insurance clinics.  Then the levels of provider knowledge pre and post education could be 
compared to that in the rural areas.  The education about BRCA screening guidelines could be 
presented at a free public offering to a high risk group of patients identified through cancer 
support groups along with a follow-up project to identify if requests for genetic referrals and 
BRCA testing in the area over the subsequent two months was statistically significant compared 
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to baseline requests for the same interventions over the prior two months. 
Dissemination 
 Dissemination plans are to present a poster presentation of the project at the National 
Nurse Practitioner Symposium from July 20-23, 2017 in Keystone, Colorado.  The student 
investigator submitted an abstract (see Appendix N) that was accepted, and the poster will be 
displayed during the conference.  The student investigator also applied for a scholarship from the 
National Nurse Practitioner Symposium to help with travel, lodging and dissemination costs, and 
was awarded a $500 scholarship.  Results and project poster will also be shared with UMKC 
faculty and students as part of degree requirements. 
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Appendix C 
 
ACE Star Model of Knowledge Transformation Applied to BRCA Screening Project 
 
Step 1: Discovery, research:  Many primary care clinics are not following the guidelines for 
BRCA screening in the primary care setting as noted upon observation as well as per literature 
review. 
 
Step 2: Evidence Summary: Conducted a thorough review of literature and it was determined 
that providers have room to improve in BRCA screening as warranted per USPSTF. 
 
Step 3: Translation of Guidelines: Per guidelines, any woman with a family history of breast, 
ovarian, tubal or peritoneal cancers should be screened with an approved screening tool.  It has 
been shown that providers lack this knowledge. 
 
Step 4: Practice Integration: Now that it is known that providers lack this knowledge, we can 
take the appropriate steps to correct it, starting with an educational session to inform and 
educate.  Once this is complete, improved screening for BRCA in the primary care will be 
possible. 
 
Step 5: Process, Outcome evaluation: I can assess the outcomes after the educational session by 
administering a follow-up questionnaire to determine whether providers gained the knowledge 
they were previously lacking.  It will also be evident in the number of referrals made to genetic 
counselors  
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Appendix D 
 
DNP Project Implementation Flow Chart 
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Appendix E 
DNP	Itemized	Cost	Table	
Provider	Training	Luncheon	 $100	
Patient	handouts	 $100	
Provider	handouts	and	questionnaire	 $100	
Poster	for	Conference	 $200	
Development	of	Provider	education	program	 $1200	(approximately	120	hours	at	$10/hour)		
Total	Cost	 $1700	
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Appendix F 
USPSTF Screening Guidelines 
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Appendix G 
Questions for Survey for Birth Care Health Care Clinicians 
     1.   Have you ever read any guidelines for referral for genetic counseling or testing for 
 BRCA1/2 mutations causing hereditary breast and ovarian cancer? 
  Yes     No I am not aware of BRCA1/2 testing  
2. In your clinical practice are you directly asking the individual if she has a personal or 
family history of breast or ovarian cancer?    Yes   No  
3. Have you referred a woman for genetic counseling regarding BRCA1/2 mutations in the 
last year?        Yes   No  
4. Have you ordered BRCA1/2 testing in the last year?  Yes   No  
5. If you answered yes to questions 3 or 4, did you use any national guidelines or 
recommendations to help with referral or testing?   Yes   No  
6. If you answered yes to question 5, what were the guidelines you used? Please check all 
that apply.  
American Cancer Society 
American Society of Clinical Oncology  
National Comprehensive Cancer Network  
United States Preventive Services Task Force  
American College of Medical Genetics  
Other (please indicate guidelines used)  
7. If you answered question 6, did you find these guidelines helpful and easy to use?         
   Yes           No                                                                                                                
8. If you answered no to question 7, how could they be improved?  
 
9. For those of you who have recommended genetic counseling or testing, were there any 
barriers you faced?                     Yes                     No  
    10. If you answered yes to question 9, please list the barriers:  
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 Please read the following clinical scenarios and answer who you would consider for 
 referral/testing for BRCA1/2.  
1. Any adult woman with breast cancer     yes no 
2. Any adult woman with any family history of breast cancer  yes no 
3. Any adult woman with any family history of ovarian cancer yes no 
4. Any adult woman with any family history of breast cancer, including at least three 
affected close relatives      yes no 
5. A close adult female relative of a person who has tested positive for a BRCA1 or BRCA2 
mutation        yes no 
6. Any adult woman with ≥ 2 first-degree relatives diagnosed with breast cancer at age <50 
         yes no 
7. Any adult woman with a first-degree relative with bilateral breast cancer   
         yes no 
8. Any adult woman with a family history of male breast cancer yes no 
9. Do you know of any racial/ethnic groups who are at higher risk for BRCA1/2 mutations? 
       yes no 
 
10. If you answered yes to question 9, please identify the relevant racial/ethnic groups.  
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Appendix H 
Education for Providers During Educational Session 
 
Breast Cancer Prevention and Early 
Detection 
What is breast cancer  
Breast cancer is a malignant tumor that starts in the cells of the breast. A malignant tumor is a 
group of cancer cells that can grow into (invade) nearby tissues or spread (metastasize) to distant 
parts of the body. Breast cancer happens mostly in women, but men can get it, too.  
The normal breast  
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To understand breast cancer, it helps to know about the normal structure of the breasts. 
 it  
 
The female breast is made up mainly of: 
  Lobules – milk-producing glands 
  Ducts – tiny tubes that carry the milk from the lobules to the nipple 
  Stroma – fatty tissue and connective tissue, blood vessels, and lymphatic vessels  
Most breast cancers start in the cells that line the ducts (ductal cancers). Some start in the cells 
that line the lobules (lobular cancers), while a small number start in other tissues.  
What are the risk factors for breast cancer?  
A risk factor is anything that affects your chance of getting a disease such as cancer. Most 
women who have one or more breast cancer risk factors never develop breast cancer, while many 
women with breast cancer have no known risk factors (other than being a woman and growing 
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older). Even when a woman with risk factors develops breast cancer, it’s hard to know just how 
much these factors might have contributed.  
Some risk factors can’t be changed – like a person's age or race. Other risk factors are lifestyle-
related, such as cancer-causing factors in the environment or personal behaviors, such as 
smoking, drinking, and diet. Some factors influence risk more than others, and your risk for 
breast cancer can change over time, due to things like aging or lifestyle.  
You may also hear about risk factors with unclear effects on breast cancer risk, or risk factors 
that are controversial or have been disproven.  
Breast cancer risk factors you cannot change  
Gender  
Simply being a woman is the main risk factor for developing breast cancer. Men can develop 
breast cancer, but it’s about 100 times more common among women than men. This is probably 
because men have less breast tissue, as well as less of the female hormones estrogen and 
progesterone, which can promote breast cancer cell growth.  
Aging  
Your risk of developing breast cancer goes up as you get older. About 1 out of 8 invasive breast 
cancers are found in women younger than 45, while about 2 of 3 invasive breast cancers are 
found in women age 55 or older.  
Inheriting certain genes  
About 5% to 10% of breast cancer cases are thought to be hereditary, meaning that they are 
caused by gene defects (called mutations) passed on from a parent.  
BRCA1 and BRCA2 gene changes: The most common cause of hereditary breast cancer is an 
inherited mutation in the BRCA1 or BRCA2 gene. In normal cells, these genes help prevent 
cancer by making proteins that help keep the cells from growing out of control. If you inherited a 
mutated copy of either gene from a parent, you have a high risk of developing breast cancer 
during your lifetime.  
Although in some families with BRCA1 mutations the lifetime risk of breast cancer is as high as 
80%, on average this risk seems to be in the range of 55 to 65%. For BRCA2 mutations the risk is 
lower, around 45%.  
Breast cancers linked to these mutations occur more often in younger women and more often 
affect both breasts than cancers not linked to these mutations. Women with these inherited 
mutations also have an increased risk for developing other cancers, particularly ovarian cancer.  
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In the United States, BRCA mutations are more common in Jewish people of Ashkenazi (Eastern 
Europe) origin than in other racial and ethnic groups, but they can occur in anyone.  
Changes in other genes: Other inherited gene mutations can also lead to breast cancer. These 
gene mutations are much less common and often do not increase the risk of breast cancer as 
much as the BRCA genes.  
  ATM: The ATM gene makes a protein that normally helps repair damaged DNA. Inheriting 2 
abnormal copies of this gene (one from each parent) causes the disease ataxia-telangiectasia. 
Inheriting one abnormal copy of this gene has been linked to a high rate of breast cancer in some 
families.  
  TP53: The TP53 gene makes a protein called p53 that helps stop the growth of abnormal cells. 
Inherited mutations of this gene cause Li-Fraumeni syndrome. People with this syndrome have 
an increased risk of breast cancer, as well as other cancers such as leukemia, brain tumors, and 
sarcomas (cancers of bones or connective tissue). This is a rare cause of breast cancer.  
  CHEK2: The Li-Fraumeni syndrome can also be caused by inherited mutations in the CHEK2 
gene. Even when it doesn’t cause this syndrome, it can increase breast cancer risk when it’s 
mutated.  
  PTEN: The PTEN gene normally helps regulate cell growth. Inherited mutations in this gene 
cause Cowden syndrome, a rare disorder in which people are at increased risk for both benign 
and malignant breast tumors, as well as growths in the digestive tract, thyroid, uterus, and 
ovaries. Defects in this gene can also cause a different syndrome called Bannayan-Riley-
Ruvalcaba syndrome that’s not thought to be linked to breast cancer risk. The syndromes caused 
by mutations in PTEN can be grouped together as PTEN Tumor Hamartoma Syndrome.  
  CDH1: Inherited mutations in this gene cause hereditary diffuse gastric cancer, a syndrome in 
which people develop a rare type of stomach cancer at an early age. Women with mutations in 
this gene also have an increased risk of invasive lobular breast cancer.  
  STK11: Defects in this gene can lead to Peutz-Jeghers syndrome. People affected with this 
disorder develop pigmented spots on their lips and in their mouths, polyps in the urinary and 
gastrointestinal tracts, and have an increased risk of many types of cancer, including breast 
cancer.  
  PALB2: The PALB2 gene makes a protein that interacts with the protein made by the BRCA2 
gene. Defects in this gene can lead to an increased risk of breast cancer. It isn’t yet clear if 
PALB2 gene mutations also increase the risk for ovarian cancer and male breast cancer.  
Genetic testing: Genetic testing can be done to look for mutations in the BRCA1 and BRCA2 
genes (or less commonly in other genes such as PTEN or TP53). Although testing can be helpful 
in some situations, the pros and cons need to be considered carefully.  
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If you are thinking about genetic testing, it’s strongly recommended that first you talk to a 
genetic counselor, nurse, or doctor qualified to explain and interpret the results of these tests. It’s 
very important to understand what genetic testing can and can’t tell you, and to  
carefully weigh the benefits and risks of genetic testing before these tests are done. Testing is 
expensive and might not be covered by some health insurance plans.  
For more information, see Genetic Testing: What You Need to Know. You might also want to 
visit the National Cancer Institute website.  
Family history of breast cancer  
Breast cancer risk is higher among women whose close blood relatives have this disease.  
Having a first-degree relative (mother, sister, or daughter) with breast cancer about doubles a 
woman’s risk. Having 2 first-degree relatives increases her risk about 3-fold.  
Although the exact risk is not known, women with a family history of breast cancer in a father or 
brother also have an increased risk of breast cancer.  
Overall, less than 15% of women with breast cancer have a family member with this disease. 
This means that most (85%) women who get breast cancer do not have a family history of this 
disease.  
Personal history of breast cancer  
A woman with cancer in one breast has an increased risk of developing a new cancer in the other 
breast or in another part of the same breast. (This is different from a recurrence (return) of the 
first cancer.) This risk is even higher if breast cancer was diagnosed at a younger age.  
Race and ethnicity  
Overall, white women are slightly more likely to develop breast cancer than are African- 
American women, but African-American women are more likely to die of this cancer. In women 
under 45 years of age, however, breast cancer is more common in African- American women. 
Asian, Hispanic, and Native American women have a lower risk of developing and dying from 
breast cancer.  
Dense breast tissue  
Breasts are made up of fatty tissue, fibrous tissue, and glandular tissue. A woman is said to have 
dense breasts (on a mammogram) when she has more glandular and fibrous tissue and less fatty 
tissue. Women with dense breasts on a mammogram have a risk of breast cancer that is 1.2 to 2 
times that of women with average breast density. Unfortunately, dense breast tissue can also 
make mammograms less accurate.  
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A number of factors can affect breast density, such as age, menopausal status, the use of certain 
drugs (including menopausal hormone therapy), pregnancy, and genetics.  
Certain benign breast conditions  
Women diagnosed with certain benign breast conditions may have an increased risk of breast 
cancer. Some of these conditions are more closely linked to breast cancer risk than others. 
Doctors often divide benign breast conditions into 3 general groups, depending on how they 
affect this risk.  
Non-proliferative lesions: These are not associated with overgrowth of breast tissue. They do 
not seem to affect breast cancer risk, or if they do, it’s to a very small extent. They include:  
• Fibrosis and/or simple cysts (sometimes called fibrocystic changes or disease)  
• Mild hyperplasia  
• Adenosis (non-sclerosing)  
• Phyllodes tumor (benign)  
• A single papilloma  
• Fat necrosis  
• Duct ectasia  
• Periductal fibrosis  
• Squamous and apocrine metaplasia  
• Epithelial-related calcifications  
• Other benign tumors (such as lipoma, hamartoma, hemangioma, neurofibroma, 
adenomyoepthelioma)  
Mastitis (infection of the breast) is not a lesion, and it doesn’t increase the risk of breast 
cancer.  
Proliferative lesions without atypia: These conditions show excessive growth of cells 
in the ducts or lobules of the breast tissue. They seem to raise a woman’s risk of breast 
cancer slightly (11⁄2 to 2 times normal). They include:  
  Usual ductal hyperplasia (without atypia)   Fibroadenoma 
  Sclerosing adenosis 
  Several papillomas (called papillomatosis)  
  Radial scar  
Proliferative lesions with atypia: In these conditions, there’s excessive growth of cells in the 
ducts or lobules of the breast tissue, and some of the cells do not look normal. These have a 
stronger effect on breast cancer risk, raising it about 4 to 5 times higher than normal. These types 
of lesions include:  
  Atypical ductal hyperplasia (ADH)  
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  Atypical lobular hyperplasia (ALH) 
Women with a family history of breast cancer and either hyperplasia or atypical  
hyperplasia have an even higher risk of developing a breast cancer. 
For more information on these conditions, see Non-cancerous Breast Conditions.  
Lobular carcinoma in situ  
In lobular carcinoma in situ (LCIS), cells that look like cancer cells are growing in the lobules of 
the milk-producing glands of the breast, but they have not grown through the wall of the lobules. 
LCIS (also called lobular neoplasia) is sometimes grouped with ductal carcinoma in situ (DCIS) 
as a non-invasive breast cancer, but it differs from DCIS in that it doesn’t seem to become 
invasive cancer if it isn’t treated.  
Women with LCIS have a 7- to 11-fold increased risk of developing cancer in either breast.  
Starting menstruation before age 12  
Women who have had more menstrual cycles (periods) because they started menstruating early 
(before age 12) have a slightly higher risk of breast cancer. The increase in risk may be due to a 
longer lifetime exposure to the hormones estrogen and progesterone.  
Going through menopause after age 55  
Women who have had more menstrual cycles because they went through menopause later (after 
age 55) have a slightly higher risk of breast cancer. The increase in risk may be due to a longer 
lifetime exposure to the hormones estrogen and progesterone.  
Previous chest radiation  
Women who as children or young adults were treated with radiation therapy to the chest area for 
another cancer (such as Hodgkin disease or non-Hodgkin lymphoma) have an increased breast 
cancer risk. This varies with the patient’s age when they got radiation. The risk is highest if the 
radiation was given during adolescence, when the breasts were  
still developing. Radiation treatment after age 40 does not seem to increase breast cancer risk.  
Diethylstilbestrol (DES) exposure  
From the 1940s through the early 1970s some pregnant women were given DES, an estrogen-
like drug, because it was thought to lower their chances of losing the baby (miscarriage). These 
women have a slightly increased risk of developing breast cancer. Women whose mothers took 
DES during pregnancy may also have a slightly higher risk of breast cancer. For more 
information, see DES Exposure: Questions and Answers.  
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Lifestyle-related risk factors for breast cancer  
Drinking alcohol  
Drinking alcohol is clearly linked to an increased risk of breast cancer. The risk increases with 
the amount of alcohol consumed. Excessive alcohol consumption is also known to increase the 
risk of developing several other cancers.  
Being overweight or obese  
Being overweight or obese after menopause increases breast cancer risk. Before menopause your 
ovaries make most of your estrogen, and fat tissue makes a small amount. After menopause 
(when the ovaries stop making estrogen), most of a woman’s estrogen comes from fat tissue. 
Having more fat tissue after menopause can increase your chance of getting breast cancer by 
raising estrogen levels. Also, women who are overweight tend to have higher blood insulin 
levels. Higher insulin levels have also been linked to some cancers, including breast cancer.  
The connection between weight and breast cancer risk is complex. For instance, risk appears to 
be increased for women who gained weight as an adult but may not be increased in those who 
have been overweight since childhood. Also, excess fat in the waist area may affect risk more 
than the same amount of fat in the hips and thighs. Researchers believe that fat cells in various 
parts of the body have subtle differences that may explain this.  
Physical activity  
Evidence is growing that physical activity in the form of exercise reduces breast cancer risk. The 
main question is how much exercise is needed. In one study from the Women’s Health Initiative, 
as little as 11⁄4 to 21⁄2 hours per week of brisk walking reduced a woman’s risk by 18%. 
Walking 10 hours a week reduced the risk a little more.  
Having children  
Women who have not had children or who had their first child after age 30 have a slightly higher 
breast cancer risk overall. Having many pregnancies and becoming pregnant at an early age 
reduces breast cancer risk overall. Still, the effect of pregnancy is different for different types of 
breast cancer.  
Birth control  
Oral contraceptives: Studies have found that women using oral contraceptives (birth control 
pills) have a slightly greater risk of breast cancer than women who have never used them. This 
risk seems to go back to normal over time once the pills are stopped. Women who stopped using 
oral contraceptives more than 10 years ago don’t appear to have any increased breast cancer risk.  
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Depot-medroxyprogesterone acetate (DMPA; Depo-Provera): This is an injectable form of 
progesterone that is given once every 3 months as birth control. A few studies have looked at the 
effect of DMPA on breast cancer risk. Women currently using DMPA seem to have an increase 
in risk, but the risk doesn’t seem to be increased if this drug was used more than 5 years ago.  
Hormone therapy after menopause  
Hormone therapy with estrogen (often combined with progesterone) has been used for many 
years to help relieve symptoms of menopause and to help prevent osteoporosis (thinning of the 
bones). This treatment goes by many names, such as post-menopausal hormone therapy (PHT), 
hormone replacement therapy (HRT), and menopausal hormone therapy (MHT).  
There are 2 main types of hormone therapy:  
• For women who still have a uterus (womb), doctors generally prescribe estrogen and 
progesterone (known as combined hormone therapy or HT). Progesterone is needed 
because estrogen alone can increase the risk of cancer of the uterus.  
• For women who’ve had a hysterectomy (those who no longer have a uterus), estrogen 
alone can be prescribed. This is commonly known as estrogen replacement therapy 
(ERT) or just estrogen therapy (ET).  
Combined hormone therapy (HT): Use of combined hormone therapy increases the 
risk of getting breast cancer. It may also increase the chances of dying from breast 
cancer.  
Estrogen therapy (ET): The use of estrogen alone after menopause does not appear to 
increase the risk of developing breast cancer.  
For more information about this topic, see Menopausal Hormone Therapy and Cancer Risk.  
Breastfeeding  
Some studies suggest that breastfeeding may slightly lower breast cancer risk, especially if it’s 
done for at least a year. But this has been hard to study, especially in countries like the United 
States, where breastfeeding for this long is uncommon.  
The reason for this possible effect may be that breastfeeding reduces a woman’s total number of 
lifetime menstrual cycles (the same as starting menstrual periods at a later age or going through 
early menopause).  
Factors with unclear effects on breast cancer risk  
For some factors, the research is not yet clear on whether they influence breast cancer risk.  
Diet and vitamin intake  
PROJECT PROPOSAL PAPER 
 
77 
Many studies have looked for a link between certain diets and breast cancer risk, but so far the 
results have been conflicting. Some studies have shown that diet may play a role, while others 
have not found that diet impacts breast cancer risk.  
Studies have also looked at vitamin levels, again with mixed results. Some studies have actually 
found an increased risk of breast cancer in women with higher levels of certain nutrients. So far, 
no study has shown that taking vitamins reduces breast cancer risk.  
Most studies have found that breast cancer is less common in countries where the typical diet is 
low in total fat, low in polyunsaturated fat, and low in saturated fat. But many studies of women 
in the United States have not linked breast cancer risk to fat in the diet. Researchers are still not 
sure how to explain this. It may be at least partly due to the effect of diet on body weight. Also, 
studies comparing diet and breast cancer risk in different countries are complicated by other 
differences (such as activity level, intake of other nutrients, and genetic factors) that might also 
alter breast cancer risk.  
More research is needed to better understand the effect of the types of fat eaten on breast cancer 
risk. But it’s clear that calories do count, and fat is a major source of calories. High-fat diets can 
lead to being overweight or obese, which is a breast cancer risk factor. A diet high in fat has also 
been shown to influence the risk of developing several other types of cancer, and intake of 
certain types of fat is clearly related to heart disease risk.  
Chemicals in the environment  
A great deal of research has been reported and more is being done to understand possible 
environmental influences on breast cancer risk.  
Chemicals in the environment that have estrogen-like properties are of special interest. For 
example, substances found in some plastics, certain cosmetics and personal care products, 
pesticides, and PCBs (polychlorinated biphenyls) seem to have such properties. These could in 
theory affect breast cancer risk.  
This issue understandably invokes a great deal of public concern, but at this time research does 
not show a clear link between breast cancer risk and exposure to these substances. Unfortunately, 
studying such effects in humans is difficult. More research is needed to better define the possible 
health effects of these and similar substances.  
Tobacco smoke  
In recent years, some studies have found that long-term heavy smoking might be linked to a 
higher risk of breast cancer. Some studies have found that the risk is highest in certain groups, 
such as women who started smoking before they had their first child. The 2014 US Surgeon 
General’s report on smoking concluded that there is “suggestive but not sufficient” evidence that 
smoking increases the risk of breast cancer.  
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Secondhand smoke: An active focus of research is whether secondhand smoke increases the 
risk of breast cancer. Both mainstream and secondhand smoke contain chemicals that, in high 
concentrations, cause breast cancer in rodents. Chemicals in tobacco smoke reach breast tissue 
and are found in breast milk.  
The evidence on secondhand smoke and breast cancer risk in human studies is unclear, at least in 
part because the link between smoking and breast cancer is also not clear. One possible 
explanation for this is that tobacco smoke may have different effects on breast cancer risk in 
smokers compared to those who are just exposed to secondhand smoke.  
A report from the California Environmental Protection Agency in 2005 concluded that the 
evidence about secondhand smoke and breast cancer is “consistent with a causal association” in 
younger, mainly pre-menopausal women. The 2014 US Surgeon General’s report concluded that 
there is “suggestive but not sufficient” evidence of a link at this point. In any case, this possible 
link to breast cancer is yet another reason to avoid secondhand smoke.  
Night work  
Several studies have suggested that women who work at night may have an increased risk of 
breast cancer. This is a fairly recent finding, and more studies are looking at this issue. Some 
researchers think the effect may be due to changes in levels of melatonin, a  
hormone whose production is affected by the body’s exposure to light. Other hormones are also 
being studied.  
Disproven or controversial breast cancer risk factors  
There are many factors that research has shown are not linked to breast cancer. You may see 
information online or hear about these disproven or controversial risk factors, but it’s important 
to learn the facts.  
Antiperspirants  
Internet and e-mail rumors have suggested that chemicals in underarm antiperspirants are 
absorbed through the skin, interfere with lymph circulation, and cause toxins to build up in the 
breast, over time leading to breast cancer.  
Based on the available evidence (including what we know about how the body works), there’s 
little if any reason to believe that antiperspirants increase the risk of breast cancer. For more 
information, see Antiperspirants and Breast Cancer Risk.  
Bras  
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Internet and e-mail rumors and at least one book have suggested that bras cause breast cancer by 
blocking lymph flow. There’s no good scientific or clinical basis for this claim, and a recent 
study of more than 1,500 women found no link between wearing a bra and breast cancer risk.  
Induced abortion  
Several studies have provided very strong data that neither induced abortions nor spontaneous 
abortions (miscarriages) have an overall effect on the risk of breast cancer. For more detailed 
information, see Is Abortion Linked to Breast Cancer?  
Breast implants  
Several studies have found that breast implants do not increase the risk of breast cancer. Implants 
can make breast tissue harder to see on standard mammograms, but extra x-ray pictures called 
implant displacement views can be used to examine the breast tissue more completely.  
Breast implants might be linked to a rare type of lymphoma called anaplastic large cell 
lymphoma. This lymphoma has rarely been found in the breast tissue around the implants. So far, 
though, there are too few cases to know if the risk of this lymphoma is really higher in women 
with implants.  
Can breast cancer be prevented?  
There is no sure way to prevent breast cancer. But there are things all women can do to help 
reduce their risk and help increase the odds that if cancer does occur, it will be found at an early, 
more treatable stage.  
Lowering your risk  
You can lower your risk of breast cancer by changing those risk factors that can be changed. (See 
“What are the risk factors for breast cancer?”)  
Body weight, physical activity, and diet have all been linked to breast cancer, so these might be 
areas where you can take action.  
Both increased body weight and weight gain as an adult are linked with a higher risk of breast 
cancer after menopause. Alcohol also increases risk of breast cancer. Even low levels of alcohol 
intake have been linked with an increase in risk.  
Many studies have shown that moderate to vigorous physical activity is linked with lower breast 
cancer risk.  
A diet that’s rich in vegetables, fruit, poultry, fish, and low-fat dairy products has also been 
linked with a lower risk of breast cancer in some studies. But it’s not clear if specific vegetables, 
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fruits, or other foods can lower risk. Most studies have not found that lowering fat intake has 
much of an effect on breast cancer risk.  
At this time, the best advice about diet and activity to possibly reduce the risk of breast cancer is 
to:  
• Get regular, intentional physical activity. To help reduce your risk of breast cancer, the 
American Cancer Society recommends that adults get at least 150 minutes of moderate 
intensity or 75 minutes of vigorous intensity activity each week (or a combination of 
these), preferably spread throughout the week.  
• Reduce your lifetime weight gain by limiting your calories and getting regular physical 
activity.  
• Avoid or limit your alcohol intake. The American Cancer Society recommends that 
women have no more than 1 alcoholic drink a day.  
For more, see American Cancer Society Guidelines on Nutrition and Physical Activity for 
Cancer Prevention.  
Women who choose to breastfeed for at least several months may also get an added 
benefit of reducing their breast cancer risk.  
Not using hormone therapy after menopause can help you avoid raising your risk.  
It’s not clear at this time if environmental chemicals that have estrogen-like properties (like those 
found in some plastic bottles or certain cosmetics and personal care products) increase breast 
cancer risk. If there is an increased risk, it’s likely to be very small. Still, women who are 
concerned may choose to avoid products that contain these substances when possible.  
For women who are or may be at increased risk  
If you are a woman at increased risk for breast cancer (for instance, because you have a strong 
family history of breast cancer, a known genetic mutation of a BRCA gene (BRCA1 or BRCA2), 
or you have had DCIS, LCIS, or biopsies that have shown pre- cancerous changes), there may be 
some things you can do to help reduce your chances of developing breast cancer. Before 
deciding which, if any, of these may be right for you, talk with your health care provider to 
understand your risk and how much any of these approaches might lower this risk.  
Genetic testing for BRCA gene mutations  
Having an inherited mutation in one of the BRCA genes greatly increases a woman’s risk of 
getting breast cancer (and some other cancers). Many women may have relatives with breast 
cancer, but in most cases this is not the result of BRCA gene mutations. Genetic testing for these 
mutations can be expensive, and the results are often not clear cut. Testing can have a wide range 
of consequences that need to be considered. It should only be done when there’s a reasonable 
suspicion that a mutation may be present.  
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Different expert groups have different recommendations about who should be considered for 
genetic testing.  
For example, the US Preventive Services Task Force (USPSTF) has guidelines aimed at women 
without a history of cancer. The USPSTF recommends that women with an increased risk of 
having a BRCA mutation based on a family history of breast, ovarian, fallopian tube, and/or 
primary peritoneal cancer should be referred to a genetics professional. The genetics professional 
can evaluate that risk further, discuss the pros and cons of testing if the woman is at high risk 
(this is called genetic counseling), and arrange for the test if the patient wishes to proceed. It’s 
important to know that BRCA mutations are rare, and only a small fraction of women who have a 
family history of breast cancer should be referred for genetic counseling and testing.  
Other medical groups offer guidelines that include women with cancer. For example, the 
National Comprehensive Cancer Network (NCCN) guidelines advise referring women 60 and 
under who have triple-negative breast cancer for genetic counseling and testing.  
If you are considering genetic testing, it’s strongly recommended that you talk first to a genetic 
counselor, nurse, or doctor qualified to explain and interpret the results of these tests. It’s very 
important to understand what genetic testing can and can’t tell you, and to  
carefully weigh the benefits and risks of testing before these tests are done. You also need to 
know that testing is expensive and may not be covered by some health insurance plans.  
Most large cancer centers employ a genetic counselor who can assess your risk of carrying a 
mutated BRCA gene, explain the risks and benefits of testing, and check with your insurance 
company to see if they will cover the test.  
For more information, see Genetic Testing: What You Need to Know. You might also want to 
visit the National Cancer Institute website.  
Breast cancer chemoprevention  
Chemoprevention is the use of drugs to reduce the risk of cancer.  
The drugs tamoxifen and raloxifene can be used to help lower breast cancer risk in certain 
women. These drugs block the action of estrogen in breast tissue. Raloxifene is only used in 
women who have gone through menopause, while tamoxifen can be used in women even if they 
haven’t gone through menopause. Experts recommend that these drugs only be used to lower 
breast cancer risk in women who are known to be at increased risk of the disease. These drugs 
can also have some side effects, so it’s important to understand the possible benefits and risks of 
taking one of the drugs.  
Other drugs are being studied to see if they can lower the risk of breast cancer. 
For more information on the possible benefits and risks of chemopreventive drugs, see  
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Medicines to Reduce Breast Cancer Risk. 
Preventive surgery for women with very high breast cancer risk  
For the few women who have a very high risk for breast cancer, surgery to remove the breasts or 
ovaries may be an option.  
Preventive (prophylactic) mastectomies: Removing both breasts before cancer is diagnosed 
can greatly reduce the risk of breast cancer (by up to 97%). Some women diagnosed with cancer 
in one breast choose to have the other, healthy breast removed as well to help prevent a second 
breast cancer. Breast removal does not completely prevent breast cancer because even a very 
careful surgeon will leave behind at least some breast cells, which might go on to become cancer.  
Some of the reasons for considering this type of surgery may include: 
  Mutated BRCA genes found by genetic testing 
  Strong family history (such as breast cancer in several close relatives)   Lobular carcinoma in 
situ (LCIS) seen on biopsy  
  Previous cancer in one breast (especially in someone with a strong family history)  
This type of surgery has been shown to be helpful in studies of large groups of women with 
certain conditions, but there’s no way to know ahead of time if this surgery will benefit any one 
woman. Some women with BRCA mutations will develop breast cancer early in life, and have a 
very high risk of getting a second breast cancer. A prophylactic mastectomy before the cancer 
occurs might add many years to their lives. But while most women with BRCA mutations 
develop breast cancer, some don’t. These women would not benefit from the surgery, but they 
would still have to deal with its aftereffects. Second opinions are strongly recommended before 
any woman decides to have this surgery.  
Prophylactic oophorectomy (removal of the ovaries): Women with a BRCA mutation may 
reduce their risk of breast cancer by 50% or more by having their ovaries surgically removed 
before menopause. This is likely because the ovaries are the main sources of estrogen in the 
body.  
It’s important that women with a BRCA mutation recognize they also have a high risk of 
developing ovarian cancer. Most doctors recommend that women with BRCA mutations have 
their ovaries surgically removed once they finish having children to lower this risk.  
Signs and symptoms of breast cancer  
Widespread use of screening mammograms has increased the number of breast cancers found 
before they cause any symptoms. Still some breast cancers are not found by mammograms, 
either because the test was not done or because even under ideal conditions mammograms do not 
find every breast cancer.  
Breast lump or mass  
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The most common symptom of breast cancer is a new lump or mass. A mass that’s painless, 
hard, and has irregular edges is more likely to be cancer, but breast cancers can be tender, soft, or 
rounded. They can even be painful. For this reason, it’s important to have any new breast mass, 
lump, or change checked by a health care provider experienced in diagnosing breast diseases.  
Other symptoms  
Other possible symptoms of breast cancer include: 
  Swelling of all or part of a breast (even if no distinct lump is felt)   Skin irritation or dimpling 
  Breast or nipple pain  
  Nipple retraction (turning inward) 
  Redness, scaliness, or thickening of the nipple or breast skin   A nipple discharge other than 
breast milk  
Sometimes breast cancer can spread to lymph nodes under the arm or around the collar bone and 
cause a lump or swelling there, even before the original tumor in the breast tissue is large enough 
to be felt.  
Although any of these symptoms can be caused by things other than breast cancer, if you have 
them, see your health care provider so that he or she can find the cause.  
American Cancer Society recommendations for 
early breast cancer detection in women without 
breast symptoms  
The importance of finding breast cancer early  
The goal of screening tests for breast cancer is to find it before it causes symptoms (like a lump 
that can be felt). Screening refers to tests and exams used to find a disease in people who don’t 
have any symptoms. Early detection means finding and diagnosing a disease earlier than might 
have happened if you’d waited for symptoms to start.  
Breast cancers found during screening exams are more likely to be smaller and still confined to 
the breast. The size of a breast cancer and how far it has spread are some of the most important 
factors in predicting the prognosis (outlook) of a woman with this disease.  
Most doctors feel that early detection tests for breast cancer help save thousands of lives each 
year, and that many more lives could be saved if even more women and their health care 
providers took advantage of these tests. Following the American Cancer Society’s guidelines for 
the early detection of breast cancer improves the chances that breast cancer can be found early 
and treated successfully.  
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For women at average risk  
These guidelines are for women at average risk for breast cancer. Women with a personal 
history of breast cancer, a family history of breast cancer, a genetic mutation known to increase 
risk of breast cancer (such as BRCA), and women who had radiation therapy to the chest before 
the age of 30 are at higher risk for breast cancer, not average- risk. (See below for guidelines for 
women at higher than average risk.)  
Women ages 40 to 44 should have the choice to start annual breast cancer screening with 
mammograms if they wish to do so. The risks of screening as well as the potential benefits 
should be considered.  
Women age 45 to 54 should get mammograms every year. 
Women age 55 and older should switch to mammograms every 2 years, or have the  
choice to continue yearly screening.  
Screening should continue as long as a woman is in good health and is expected to live 10 more 
years or longer.  
All women should be familiar with the known benefits, limitations, and potential harms 
associated with breast cancer screening. They should also be familiar with how their breasts 
normally look and feel and report any changes to a health care provider right away.  
Mammograms  
Regular mammograms can often help find breast cancer at an early stage, when treatment is most 
likely to be successful. A mammogram can find breast changes that could be cancer years before 
physical symptoms develop. Results from many decades of research clearly show that women 
who have regular mammograms are more likely to have breast cancer found early, less likely to 
need aggressive treatment (like surgery to remove the entire breast [mastectomy] and 
chemotherapy), and more likely to be cured.  
Mammograms are not perfect. They miss some cancers. And sometimes more tests will be 
needed to find out if something found on a mammogram is or is not cancer. There’s also a small 
possibility of being diagnosed with a cancer that never would have caused any problems had it 
not been found during screening. It‘s important that women getting mammograms know what to 
expect and understand the benefits and limitations of screening.  
Clinical breast exam and breast self-exam  
Research does not show a clear benefit of physical breast exams done by either a health 
professional or by yourself for breast cancer screening. Due to this lack of evidence, regular 
clinical breast exam and breast self-exam are not recommended. Still, all women should be 
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familiar with how their breasts normally look and feel and report any changes to a health care 
provider right away.  
For women at higher than average risk  
Women who are at high risk for breast cancer based on certain factors should get an MRI 
and a mammogram every year. This includes women who:  
• Have a lifetime risk of breast cancer of about 20% to 25% or greater, according to risk 
assessment tools that are based mainly on family history (such as the Claus model – see 
below)  
• Have a known BRCA1 or BRCA2 gene mutation  
• Have a first-degree relative (parent, brother, sister, or child) with a BRCA1 or BRCA2  
gene mutation, and have not had genetic testing themselves  
• Had radiation therapy to the chest when they were between the ages of 10 and 30 years  
• Have Li-Fraumeni syndrome, Cowden syndrome, or Bannayan-Riley-Ruvalcaba 
syndrome, or have first-degree relatives with one of these syndromes  
The American Cancer Society recommends against MRI screening for women 
whose lifetime risk of breast cancer is less than 15%.  
There’s not enough evidence to make a recommendation for or against yearly MRI 
screening for women who have a moderately increased risk of breast cancer (a 
lifetime risk of 15% to 20% according to risk assessment tools that are based mainly 
on family history) or who may be at increased risk of breast cancer based on certain 
factors, such as:  
• Having a personal history of breast cancer, ductal carcinoma in situ (DCIS), lobular 
carcinoma in situ (LCIS), atypical ductal hyperplasia (ADH), or atypical lobular 
hyperplasia (ALH)  
• Having dense breasts (“extremely” or “heterogeneously” dense) as seen on a 
mammogram  
If MRI is used, it should be in addition to, not instead of, a screening mammogram. This 
is because although an MRI is a more sensitive test (it’s more likely to detect cancer than 
a mammogram), it may still miss some cancers that a mammogram would detect.  
For most women at high risk, screening with MRI and mammograms should begin at age 
30 years and continue for as long as a woman is in good health. But because the evidence 
is limited about the best age at which to start screening, this decision should be based on 
shared decision-making between patients and their health care providers, taking into 
account personal circumstances and preferences.  
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Tools used to assess breast cancer risk  
Several risk assessment tools, with names such as the Gail model, the Claus model, and 
the Tyrer-Cuzick model, are available to help health professionals estimate a woman’s 
breast cancer risk. These tools give approximate, rather than precise, estimates of breast 
cancer risk based on different combinations of risk factors and different data sets.  
Because the different tools use different factors to estimate risk, they may give different risk 
estimates for the same woman. For example, the Gail model bases its risk estimates on certain 
personal risk factors, like current age, age at first menstrual period and history of prior breast 
biopsies, along with any history of breast cancer in first-degree relatives. In contrast, the Claus 
model estimates risk based only on family history of breast cancer in both first and second-
degree relatives. These 2 models could easily give different estimates for the same person.  
Risk assessment tools (like the Gail model, for example) that are not based mainly on family 
history are not appropriate to use with the ACS guidelines to decide if a woman should have 
MRI screening. The use of any of the risk assessment tools and its results should be discussed by 
a woman with her health care provider.  
More on MRI as a screening test  
It’s recommended that women who get a screening MRI do so at a facility that can do an MRI-
guided breast biopsy at the same time if needed. Otherwise, the woman will have to have a 
second MRI done at another facility when she has the biopsy.  
There’s no evidence right now that MRI is an effective screening tool for women at average risk. 
While MRI is more sensitive than mammograms, it also has a higher false- positive rate. (This 
means it’s more likely to find something that turns out not to be cancer.) This would lead to 
unneeded biopsies and other tests in many of the women screened, which can lead to a lot of 
worry and anxiety.  
The American Cancer Society believes the use of mammograms and MRI (in women at high 
risk), according to the recommendations outlined above, offers women the best chance to reduce 
their risk of dying from breast cancer. This approach is clearly better than any one exam or test 
alone.  
See Mammograms and Other Breast Imaging Tests for more details on mammograms, breast 
MRI, breast ultrasound, and other tests that might be used to diagnose breast cancer or find it 
early.  
Paying for breast cancer screening  
In the United States, certain laws require most private health plans, Medicaid, and Medicare to 
cover early detection services for breast cancer screening.  
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Laws requiring coverage for breast cancer screening  
Federal law  
Coverage of mammograms for breast cancer screening is mandated by the Affordable Care Act, 
which provides that these be given without a co-pay or deductible in plans that started after 
August 1, 2012. This doesn’t apply to health plans that were in place before the law was passed 
(called grandfathered plans). You can find out the date your insurance plan started by contacting 
your health insurance plan administrator. Even grandfathered plans may still have coverage 
requirements based on state laws, which vary, and other federal laws.  
State laws  
Many states require that private insurance companies, Medicaid, and public employee health 
plans provide coverage and reimbursement for specific health services and procedures. The 
American Cancer Society (ACS) supports these kinds of patient protections, particularly when it 
comes to evidence-based cancer prevention, early detection, and treatment services.  
The only state without a law ensuring that private health plans cover or offer coverage for 
screening mammograms is Utah. Laws on coverage vary slightly from state to state, so check 
with your insurer to see what’s covered.  
Note: State laws don’t affect self-insured (self-funded) health plans.  
Insurance coverage for breast cancer screening  
Self-insured (self-funded) plans  
Many employers offer self-insured (self-funded) plans. These plans pay employee health care 
costs from the employer’s own funds, even though they usually contract with another company 
to track and pay claims.  
Self-insured or self-funded plans do not have to follow state laws about breast cancer screening. 
Instead, they are governed by the Affordable Care Act (ACA), and are required to cover breast 
cancer screening. The exception is any self-insured plan that was in effect before the ACA was 
passed. These plans are called grandfathered, and they don’t have to provide coverage based on 
what the ACA says.  
You can find out if your health plan is self-insured by contacting your insurance administrator at 
work or reading your Summary of Plan Benefits. Women covered by self-insured employer plans 
should check to find out what breast cancer early detection services are covered.  
Medicare  
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As a part of the Affordable Care Act, Medicare covers the full cost of a screening mammogram 
once every 12 months for all women with Medicare aged 40 and over. Diagnostic mammograms 
are covered with a 20% co-pay after the part B deductible is met.  
Medicaid  
All state Medicaid programs plus the District of Columbia cover screening mammograms. This 
coverage may or may not conform to American Cancer Society guidelines. State Medicaid 
offices should be able to give you details about screening coverage in your state.  
National Breast and Cervical Cancer Early Detection Program  
States are making breast cancer screening more available to medically underserved women 
through the Centers for Disease Control and Prevention’s (CDC’s) National Breast and Cervical 
Cancer Early Detection Program (NBCCEDP). The NBCCEDP attempts to reach as many 
women in medically underserved communities as possible, including older women, women 
without health insurance, and women who are members of racial and ethnic minorities. Age and 
income requirements vary by state.  
The program provides both screening and diagnostic services to low-income, uninsured, and 
underserved women for free or at very low cost, including:  
  Mammograms 
  Diagnostic testing for women whose screening results are abnormal   Surgical consultations 
  Referrals to treatment  
Each state’s Department of Health will have information on how to contact the nearest 
NBCCEDP screening and early detection program in your area. To learn more, contact the CDC 
at 1-800-CDC-INFO (1-800-232-4636) or online at www.cdc.gov/cancer/nbccedp.  
We have a lot more information you might find helpful. You can read more online or call one of 
our cancer information specialists at 1-800-227-2345 any time, day or night.  
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Appendix N 
Abstract for Dissemination 
Improved BRCA Risk Screening Among Women in Primary Care Following Provider 
Education 
Jentry Wheaton, RN, BSN, DNP Student 
University of Missouri-Kansas City  
Kansas City, MO 
 
Objective: The purpose of this project is to determine if a BRCA gene mutation educational 
session regarding hereditary breast and ovarian cancers, among primary care providers will 
increase provider’s knowledge related to Hereditary Breast and Ovarian Cancer (HBOC) 
Syndrome. 
Background/Significance: There are two types of BRCA (BReast CAncer) genes, BRCA 1 and 
BRCA 2.  The BRCA genes work as tumor suppressors, which function by controlling the 
assembly of macromolecular structures that monitor segregation and duplication of 
chromosomes.  When these genes are malfunctioning, or have a mutation, they are more 
susceptible to human malignancies, particularly breast and ovarian tumors.   
Design: The project is a quality improvement project in order to assess provider knowledge 
before and after educational intervention. 
Methodology: Providers within the primary care clinic will complete a questionnaire to 
determine their current level of understanding regarding screening for increased risk of BRCA 
mutations.  Directly following, an educational session will be provided to discuss current 
screening guidelines from the United States Preventive Services Task Force as well as the 
American Cancer Society and implications of BRCA gene mutations for female patients.  Next, 
providers will complete the same questionnaire to determine if their knowledge has increased 
following the educational session. 
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Results: It is expected that providers will better understand the purpose of screening for BRCA 
mutations in the primary care setting.  Data analysis will begin January 2017. 
Implications for Nursing Practice: The usefulness of this intervention has the potential to 
improve provider knowledge and awareness about BRCA mutation screening in the primary care 
setting.  If this project is successful, this could lead to a decrease in the diagnosis of advanced 
stage breast cancer, which leads to decreased health care costs. 
 
 
